AD-Nanotech

AD-Nanotech is a clinical-stage biotechnology company based in Taiwan that specializes in the development of advanced nanoparticle-based drug delivery systems. The company's proprietary platform is designed to enhance the therapeutic index of potent anti-cancer agents by improving their solubility, stability, and targeted delivery to tumor tissues. Its lead clinical candidate, AD-101, is a nanoparticle formulation currently being evaluated for the treatment of hepatocellular carcinoma. By leveraging its expertise in nanotechnology, AD-Nanotech aims to reduce the systemic toxicity associated with conventional chemotherapy while maximizing efficacy. The company continues to expand its pipeline to address various solid tumors with high unmet medical needs.